Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
67%(6 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
8
80%
Ph phase_3
2
20%

Phase Distribution

0

Early Stage

8

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
8(80.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
90.0%
Most Advanced
Phase 3

Trials by Phase

Phase 28 (80.0%)
Phase 32 (20.0%)

Trials by Status

completed990%
terminated110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma

NCT00006695
terminatedphase_3

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00004874
completedphase_2

Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

NCT00476047
completedphase_2

Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

NCT00933335
completedphase_3

Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma

NCT00268983
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00006695Phase 2

Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma

Completed
NCT00004874Phase 3

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Terminated
NCT00476047Phase 2

Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

Completed
NCT00933335Phase 2

Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

Completed
NCT00268983Phase 3

Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma

Completed
NCT00938041Phase 2

Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody

Completed
NCT00989664Phase 2

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

Completed
NCT00107380Phase 2

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Completed
NCT00073931Phase 2

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed
NCT00003784Phase 2

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed

All 10 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
10